Soybean transphosphatidylated phosphatidylserine (SB -t PS) was prepared from soybean phosphatidylcholine by transphos phatidylation using phospholipase D, and the fatty acids composition and pharmacological properties were compared with those of bovine brain cortex-derived phosphatidylserine (BC-PS) which was reported to im prove cognitive disorders of senile dementia patients by oral administra tion (300mg/day). The molecular species of SB-tPS are rich in linoleic and palmitic acids whereas those of BC-PS are stearic and oleic acids. Despite the differences in fatty acid composition, SB-tPS displayed signifi cant activities on the increase in brain glucose concentrations in mice (79 mg/kg, i.v.) and the restoration of scopolamine-induced amnesia in rats (60mg/kg, i.p.) as did BC-PS. These results suggest the possibility that SB-tPS may prevent and/or improve senile dementia by oral administra tion.
In 1986, it was first reported that the oral administration (300mg/day) of bovine brain cortex-derived phosphatidylserine (BC-PS) to patients with senile dementia improved their cognitive disorders (1) . Since then, the effectiveness of this phospholipid has been confirmed by several double-blind, placebo-controlled studies in Europe and the USA (2) (3) (4) (5) . Especially, one recent clinical trial on 494 elderly patients (3) demonstrated the benefit of taking BC-PS as an anti-dementia agent improving the behavior and cognitive performance without remarkable side effects.
It is known that phosphatidylcholine (PC) can also improve cognitive disor ders. However, unlike BC-PS, the anti-dementia effects of PC have been proven by a combination with cholinesterase inhibitors such as tetrahydroaminoacridine, and the efficacy dose of PC was about 30 times larger than that of BC-PS (6) . Therefore, the anti-dementia mechanism of BC-PS would be different from that of PC which is considered to improve brain function by supplying choline for acetylcholine synthesis.
The efficacy dose of BC-PS (300mg/day) is not extraordinarily higher than the estimated daily intake (80mg) (7), therefore, it could be possible to claim this phospholipid as a food supplement to prevent and/or improve senile dementia. However, in terms of safety, the brain cortex is not a suitable material for food use, because some encephalopathies such as mad cow disease (bovine spongiform encephalopathy) or Kuru disease in humans are orally infectious through prion contaminated brain (8) . In addition, the content of phosphatidylserine in brain cortex is small (about 3g/one bovine brain cortex) (9) and there are no known natural and safe sources which contain phosphatidylserine in amounts adequate for use as a food supplement.
To overcome these problems, a transphosphatidylation reaction using phos pholipase D (10) was applied to produce phosphatidylserine from soybean lecithin. In this reaction, PC is a donor of phosphatidyl residue and L-serine is an acceptor. However, the fatty acid composition of the transphosphatidylated phosphatidyl serine from soybean lecithin is probably different from that of BC-PS, the structure of which is mainly confined to a 1-stearoyl-2-oleoyl-sn-glycero-3-phosphoserine. Therefore, we investigated the pharmacological activities of soybean transphos phatidylated phosphatidylserine (SB-tPS) in rodents in comparison with those of BC-PS to evaluate the suitability of SB-tPS as a dementia-preventing food supple ment. 
MATERIALS AND METHODS

Materials
RESULTS
Fatty acid composition of SB-tPS As show in Table 1 , the fatty acid composition of SB-tPS was almost identical with that of PC80TM from which SB-tPS was made, but was different from that of BC-PS. With respect to 1-position fatty acids, SB-tPS mainly possesses linoleic acid (40.0%) or palmitic acid (35.9%) whereas most of BC-PS comprises stearic acid (87.9%). Regarding the 2-position, SB-tPS comprises mostly linoleic acid (76.6%) while BC-PS comprises oleic acid (72.2%).
Increase of the glucose concentration by intravenous injection of phosphatidylserine or lysophosphatidylserine into mice As shown in Tables 2 and 3 , intravenous injection of SB-tPS or lyso-SB-tPS (lysophosphatidylserine from SB-tPS) into mice tail veins significantly increased the glucose concentrations in both the brain and serum, although the level of lyso-SB-tPS was somewhat lower than that of lyso-BC-PS (Table 3) . Table 4 . Effects of intraperitoneal injection of phosphatidylserines (60mg/kg) on the scopolamine-induced amnesia measured by passive avoidance behavior of rats.
a) Rats distributed/rats tested . b)p values of difference from group 2 (treated with scopolamine alone) determined by the Mann Whitney's U-test.
Restoration of scopolamine-induced amnesia in rats by intraperitoneal injection of phosphatidylserine As shown in Table 4 , 9 out of 15 rats treated with scopolamine alone entered the dark chamber within 30s, whereas all of the control rats given Tris-HCl buffer stayed in the lighted chamber over 300s. When phosphatidylserine (SB-tPS or BC-PS) and scopolamine were administered into different points of an abdomen, the latency of the majority of mice exceeded 300s. Consequently, the reaction latency was significantly prolonged compared with the group treated with scopol amine alone (p<0.01 for SB-tPS, p<0.05 for BC-PS).
DISCUSSION
In the present study, the pharmacological action of SB-tPS was compared with that of BC-PS which reportedly improves cognitive disorders of senile dementia patients. So far, it is not clear whether or not the pharmacological actions of phospholipids containing completely different molecular species from BC-PS, like SB-tPS (Table 1) , are similar to BC-PS.
Bruni et al. (13) first reported that the intravenous injection of BC-PS increased the brain glucose concentrations of mice. In addition, it was proven that a lyso-form of BC-PS was similarly active (14) . As shown in Tables 2 and 3 , SB-tPS or lyso-SB-tPS significantly increased the serum and brain glucose concen trations, indicating that the pharmacological activity of those soybean phospholipid derivatives are comparable to BC-PS. The serum glucose augmentation by BC-PS was suppressed by an adrenolytic agent (13), and was not observed in mast cell deficient mice (14) , which may reflect adrenaline-induced hepatic glycogenolysis through mast cell activation. While this hyperglycemic state is one of the most plausible reasons for the brain glucose augmentation, a reduced energy-expenditure accompanied with a diminished carbohydrate catabolism is also possible, because the efficiency of the oxidative phosphorylation in the brains of Alzheimer's disease patients was lower than that of normal subjects (15) . Contrary to our results, the purified soybean phosphatidylserines (soybean PS) were reported to have little or no effect on the glucose state (13), though we cannot explain this inconsistency.
Zanotti et al. (16) reported that the intraperitoneal injection of BC-PS restored scopolamine-induced amnesia in rats, which seemed to offer a clue to the anti dementia mechanism of phosphatidylserine. Because scopolamine is an acetyl choline receptor antagonist, the results in Table 4 suggest that SB-tPS affects on brain acetylcholine metabolism. Casamenti et al. (17) reported that the successive administration of BC-PS reversed the age-dependent decrease in cortical acetyl choline release in rats; therefore, SB-tPS may also improve memory dysfunction in aged animals by ameliorating their acetylcholine release.
Up until now, no information has been available about the pharmacological properties of phosphatidylserines other than BC-PS and soybean PS. Furthermore, it is not yet clear whether or not the characteristic stearoyloleate of BC-PS is an essential structure for its actions on brain functions. The present data show that SB-tPS has almost the same activities as BC-PS in regards increasing the brain glucose concentration and restoring scopolamine-induced amnesia, which suggests that a specific combination of fatty acids is not necessarily required for the improvement of brain function.
Although the chronic oral treatment of BC-PS to aged rats (16) or neonatal mice (18) has already been reported to improve cognitive abilities, further animal experiments, especially oral treatment of SB-tPS, are needed to confirm the useful ness of SB-tPS as an anti-dementia food material.
